Systemic inflammatory markers neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratios as therapy response markers of epithelial ovarian cancer in Adam Malik Hospital Medan
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20262513Keywords:
Epithelial ovarian cancer, Blood inflammatory markers, Therapy responseAbstract
Background: Ovarian cancer has a complex pathological type, high recurrence rate, poor therapy response and prognosis. In recent years, examination of inflammatory markers of ovarian cancer therapy response has been developed. Systemic inflammatory response is closely related to cancer initiation, development and metastasis so that it can be used as a therapy response of ovarian cancer. This study aims to determine the systemic inflammatory markers NLR, PLR and MLR as a therapy response of epithelial ovarian cancer patients stage III after optimal debulking and complete adjuvant chemotherapy.
Methods: This study is an observational analytical study with a diagnostic test design on systemic blood inflammatory markers NLR, PLR, and MLR as marker of therapy response of epithelial ovarian cancer patients at Adam Malik Hospital Medan using retrospective data. This study involved a total of 135 patients with stage III epithelial ovarian cancer patients who had undergone optimal debulking and complete adjuvant chemotherapy from January 1 2018 to December 31 2022 with complete follow-up for 1 year.
Results: Based on the results of ROC curve analysis, the optimal cut off value for NLR was 2.4 (AUC: 73.2%, 95% CI: 64.1-82.4%, p<0.001) with a sensitivity of 69.9% and a specificity of 66.67%. The optimal cut off value for PLR was 173 (AUC: 82%, 95% CI: 74.4-89.5%, p<0.001) with a sensitivity of 77.4% and a specificity of 73.8%. The optimal cut off value for MLR was 0.5 (AUC: 66.2%, 95% CI: 54.9-77.6%, p<0.001) with a sensitivity of 71% and a specificity of 69%. There was a significant association between the NLR, PLR, and MLR values with the response to therapy in stage III epithelial ovarian cancer patients who had undergone debulking laparotomy and complete adjuvant chemotherapy (p<0.001). The result of multivariate analysis showed that the most dominant variable in predicting therapy response of epithelial ovarian cancer patients was PLR with the largest OR value of 7.823 (95% CI 7.268-187.947).
Conclusions: The optimal cut-off values of NLR, PLR, MLR statistically significant with therapy response of stage III epithelial ovarian cancer who had undergone optimal debulking and complete adjuvant chemotherapy. Increased levels of NLR, PLR, and MLR were more likely to be associated with a non-complete therapy response.
References
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.
Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:3773.
International Agency for Research on Cancer. Global Cancer Observatory: Indonesia fact sheet 2022. Lyon: International Agency for Research on Cancer; 2022.
Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 2021;137(1):108-21.
Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2021;87:17-38.
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31-46.
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-50.
Zahav MH, Shahar IB, Zidan MD, Ben-David Y, Cohen A, Levy N, et al. The use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic factors before and after treatment of epithelial ovarian cancer. Clin Oncol. 2023;8:1980.
Zhang CL, Jiang XC, Li Y, Wang Y, Liu J, Chen X, et al. Independent predictive value of blood inflammatory composite markers in ovarian cancer. J Ovarian Res. 2023;16:36.
Galli F, Aguilera JV, Palermo B, Markovic SN, Nisticò P, Signorelli D, et al. Relevance of immune cell and inflammatory biomarkers in ovarian cancer. Cancers (Basel). 2023.
Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022;22:173-87.
Jeerakornpassawat D, Suprasert P. Potential predictors for chemotherapeutic response in epithelial ovarian cancer. Obstet Gynecol Sci. 2020;63:55-63.
Guo Y, Shi D, Zhang J, Mao S, Wang L, Zhang W, et al. Platelets and cancer progression. Signal Transduct Target Ther. 2023;8:310
Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799-820.
Rosaudyn R, Mutiani F, Yuliati I, Siregar A, Putri NM, Hidayat R, et al. Prognostic value of neutrophil-to-lymphocyte ratio and fibrinogen levels in ovarian cancer. Med J Indones. 2023;32.
Kovács AR, Sulina A, Kovács KS, Tóth E, Berczi L, Németh G, et al. Prognostic significance of preoperative neutrophil-to-lymphocyte, monocyte-to-lymphocyte, and platelet-to-lymphocyte ratios in epithelial ovarian cancer. Diagnostics (Basel). 2023;13.
Liontos M, Andrikopoulou A, Koutsoukos K, Markellos C, Dimopoulos MA, Bamias A, et al. Neutrophil-to-lymphocyte ratio and chemotherapy response score in epithelial ovarian cancer. J Ovarian Res. 2021;14.
Plaja A, Teruel I, Ochoa-de-Olza M, Armiñán A, Muñoz-Couselo E, Galluzzi L, et al. Prognostic role of neutrophil-, monocyte-, and platelet-to-lymphocyte ratios in ovarian cancer. Int J Mol Sci. 2023;24.
Tuntinarawat P, Tangmanomana R, Kittisiam T. Association between alteration of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio after chemotherapy in epithelial ovarian cancer. Gynecol Oncol Rep. 2024.
Sanna E, Tanca L, Cherchi C, Fois SS, Piras F, Manca A, et al. Decrease in neutrophil-to-lymphocyte ratio during neoadjuvant chemotherapy as a prognostic marker in advanced ovarian cancer. Diagnostics (Basel). 2021;11.
Winarto H, Welladatika A, Habiburrahman M, Pratama G, Nuranna L, Sutrisna B, et al. Overall survival and related factors in epithelial ovarian cancer. Open Access Maced J Med Sci. 2022;10.
Sastra WIG, Aditya PPK, Gradiyanto OE, Putra IB, Mahendra IGAA, Wiradana PA, et al. Predictive value of preoperative inflammatory markers in epithelial ovarian cancer. Cancer Biomark. 2022;34.
Winarno GNA, Pasaribu M, Susanto H, Siregar AA, Lubis HP, Harahap A, et al. The platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as predictors of epithelial ovarian cancer outcome. Asian Pac J Cancer Prev. 2021;22.
Hu Q, Shen G, Li Y, Zhang X, Wang H, Liu J, et al. Lymphocyte-to-monocyte ratio after primary surgery predicts survival in epithelial ovarian cancer. Front Oncol. 2023;13.
Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):124.
Downloads
Published
How to Cite
Issue
Section
